{"id":"opc-1085el-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the production of pro-inflammatory cytokines, thereby reducing inflammation in the eye. This is achieved through its mechanism of action, which is not fully elucidated.","oneSentence":"OPC-1085EL ophthalmic solution is an anti-inflammatory agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:24.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry eye disease"}]},"trialDetails":[{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":204},{"nctId":"NCT02105285","phase":"PHASE3","title":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":193},{"nctId":"NCT02105272","phase":"PHASE3","title":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":237},{"nctId":"NCT02108288","phase":"PHASE1","title":"Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPC-1085EL ophthalmic solution","genericName":"OPC-1085EL ophthalmic solution","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-1085EL ophthalmic solution is an anti-inflammatory agent. Used for Treatment of dry eye disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}